Guangzhou LBP Medicine Science & Technology Co Ltd
688393
Company Profile
Business description
Guangzhou LBP Medicine Science & Technology Co Ltd is engaged in production and sales of in vitro diagnostic reagents and instruments. The company's products include Fluorescence in situ hybridization (FISH) series; Immunohistochemistry (IHC) series; Liquid - based cytology (LBP) series; PCR series; and medical laboratory.
Contact
Building 7, No. 11, Nanxiang 3rd Road
Guangzhou High-tech Industrial Development Zone
Guangdong Province
Guangzhou510663
CHNT: +86 2032299997
Sector
Healthcare
Stock type
Defensive
Industry
Medical Instruments & Supplies
Fiscal Year End
31 December 2025
Employees
796
Stocks News & Analysis
stocks
Another incredible quarter from Microsoft
We were wrong when we thought last quarter would be hard to top.
stocks
10 best US dividend aristocrats to buy now—including a surprise outperformer
These undervalued stocks with wide and narrow moats have increased their dividends for 25 consecutive years or more.
stocks
Leading ASX players in this field look materially overvalued
We raise our Fair Value estimates but still think that current share prices rely on overly optimistic expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,917.10 | 81.90 | -0.91% |
| CAC 40 | 7,546.16 | 225.81 | -2.91% |
| DAX 40 | 23,425.97 | 639.50 | -2.66% |
| Dow JONES (US) | 43,468.73 | 662.25 | -1.50% |
| FTSE 100 | 9,068.58 | 64.23 | -0.70% |
| HKSE | 24,507.81 | 265.52 | -1.07% |
| NASDAQ | 20,611.95 | 510.50 | -2.42% |
| Nikkei 225 | 40,799.60 | 270.22 | -0.66% |
| NZX 50 Index | 12,729.40 | 94.34 | -0.74% |
| S&P 500 | 6,223.99 | 115.40 | -1.82% |
| S&P/ASX 200 | 8,662.00 | 80.80 | -0.92% |
| SSE Composite Index | 3,559.95 | 13.26 | -0.37% |